ArticleAlzheimer's & dementia (New York, N. Y.)2017
The Effect of Statins on Rate of Cognitive Decline in Mild Cognitive Impairment.
Article in Alzheimer's & dementia (New York, N. Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- A simple nomogram to predict the onset of dementia in mild cognitive impairment: A retrospective study.Journal of Alzheimer's disease : JAD · 2025Article
- Managing Hypercholesterolemia in Adults Older Than 75 years Without a History of Atherosclerotic Cardiovascular Disease: An Expert Clinical Consensus From the National Lipid Association and the American Geriatrics Society.Journal of the American Geriatrics Society · 2025Article
- Cognitive function in dyslipidemia patients: exploring the impact of statins.Frontiers in neurology · 2024Article
- Cholesterol, Atherosclerosis, and APOE in Vascular Contributions to Cognitive Impairment and Dementia (VCID): Potential Mechanisms and Therapy.Frontiers in aging neuroscience · 2021Article
- The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer's disease.Alzheimer's research & therapy · 2020Article
- Statin Use and Risk of Cognitive Decline in the ADNI Cohort.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2020Observational
- Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseases.Alzheimer's & dementia (New York, N. Y.) · 2020Article
- Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer's disease.Molecular brain · 2019Review
- Insights into Computational Drug Repurposing for Neurodegenerative Disease.Trends in pharmacological sciences · 2019Review
- Quantitative Systems Pharmacology Model for Alzheimer Disease Indicates Targeting Sphingolipid Dysregulation as Potential Treatment Option.CPT: pharmacometrics & systems pharmacology · 2018Article
- Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia?Alzheimer's research & therapy · 2018Article
- Atorvastatin Attenuates Cognitive Deficits and Neuroinflammation Induced by AβJournal of molecular neuroscience : MN · 2018Article
- The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration.Metabolic brain disease · 2017Review
- Adherence to Statins Use and Risk of Dementia among Patients with Diabetes and Comorbid Hyperlipidemia.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveThis study's aims are to identify whether or not a relationship between statin use and rate of cognitive decline exists.
backgroundThe relationship between statins and MCI has been investigated in the past with the evidence showing mixed results.
methods768 subjects were identified with MCI. Subjects were stratified into 6 possible groups according to ApoE4 status and statin use and assessed for decline in cognitive function.
resultsAll cognitive assessments trended towards less decline with statin use. ADAS11 showed the biggest difference in mean change between statin users and nonusers (-0.82 vs. -1.22 respectively). Change reached marginal significance on the ADAS11 when stratified by ApoE4 negative subjects.
conclusionAll cognitive assessments trended towards less decline when subjects were concurrently treated with a statin, supporting the position that statins do not have a net negative effect on cognitive assessment and suggests a potential treatment benefit.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.